Breaking News

MolecularMD’s CambridgeLab Gains CLIA Certification

April 4, 2014

Next-Gen Sequencing lab meets quality standards

MolecularMD has received certification of its Next Generation Sequencing (NGS) clinical lab in Cambridge, MA under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. CLIA establishes quality standards for lab testing to help ensure accuracy, reliability and timeliness of test results, regardless of where the test is performed. 
The Cambridge lab provides custom solutions for NGS-based companion diagnostics to support early stage and pivotal clinical studies. The company has developed a range of NGS cancer panels and specializes in the design and validation of tissue and blood-based panels to explore drug-relevant genomic regions for evaluations and prospective clinical trial enrollment. 
"We are working productively with several top pharmaceutical clients to meet their biomarker evaluation and companion diagnostic requirements, supporting early stage proof-of-concept as well as drug/diagnostic co-development programs for FDA approval. We are pleased to now offer CLIA-certified NGS services in Cambridge; this capability enhances our flexibility and broadens our service offerings to accommodate clinical trial testing needs," said Dr. Glenn Miller, executive vice president and chief technology officer.
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Biopharmaceutical Contract Manufacturing Capacity Expansions

    Biopharmaceutical Contract Manufacturing Capacity Expansions

    William Downey , HighTech Business Decisions||June 2, 2015
    Biopharma contract manufacturing market continues to expand, expected to grow 8% over the next five years